指南与共识泌尿与男性生殖病理

GUPS与ISUP关于前列腺导管内癌的联合专家共识建议

The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate.
指南 / 共识 · Histopathology · 2026-01-01

针对前列腺导管内癌(IDCP)分级实践推荐冲突,GUPS与ISUP组织32人专家 panel 采用改良 Delphi 流程达成共识。共识明确 IDCP 诊断标准、AIP 术语使用、分级原则及报告规范,旨在减少观察者差异并统一临床沟通。

要点

  • IDCP诊断应基于Guo和Epstein标准,疑难病例辅以基底细胞免疫组化。
  • AIP仅用于疑为IDCP但标准未完全满足者,报告为「AIP,可疑IDCP」。
  • 伴浸润性癌时IDCP一般纳入Gleason分级,纯IDCP及AIP不评分。

核心结论

  • GUPS与ISUP联合专家共识为IDCP和AIP的诊断、术语、分级和报告提供统一建议。

研究设计与样本

  • 32人专家 panel(5名核心成员、25名泌尿病理专家、2名泌尿外科专家)采用改良Delphi流程多轮咨询和投票。
  • 共识定义为至少67%同意,并于2025年USCAP年会讨论补充。

主要发现

  • IDCP最常见反映浸润性前列腺癌的逆行播散。
  • IDCP诊断应基于Guo和Epstein标准,疑难病例辅以基底细胞免疫组化。
  • AIP术语仅用于疑为IDCP但标准未完全满足的模棱两可增殖,报告为「AIP,可疑IDCP」。
  • 伴浸润性前列腺癌时,IDCP一般应纳入Gleason分级,不论Grade Group;但显著少数(30%)支持若浸润成分仅为Gleason模式3则排除IDCP于Gleason评分。
  • 纯IDCP(不伴浸润性前列腺癌)和AIP(可疑IDCP)不应分级;IDCP与浸润性癌空间分离时不应纳入后者分级。

关键数值与推荐

  • IDCP诊断标准:Guo和Epstein标准,疑难病例辅以基底细胞免疫组化。
  • AIP报告用语:「AIP,可疑IDCP」。
  • 伴浸润性癌时IDCP一般纳入Gleason分级;纯IDCP和AIP不评分。
  • 30%专家支持浸润成分仅为Gleason模式3时排除IDCP于Gleason评分。
  • 纯IDCP或GP3+IDCP罕见情形应考虑高级或专职泌尿病理医生二次意见及多学科讨论。

临床怎么用

  • 病理医生应按Guo和Epstein标准诊断IDCP,疑难时加做基底细胞免疫组化。
  • 对疑为IDCP但标准未完全满足者使用「AIP,可疑IDCP」术语报告。
  • 伴浸润性癌时将IDCP纳入Gleason分级,纯IDCP和AIP不评分。
  • 纯IDCP或GP3+IDCP情形建议二次意见和多学科讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Conflicting practice recommendations regarding the grading of intraductal carcinoma of the prostate (IDCP) from two leading uropathology societies, the Genitourinary Pathology Society (GUPS) and the International Society of Urological Pathology (ISUP), are confusing for both pathologists and treating clinicians. The objectives of this consultation were to clarify unresolved issues regarding IDCP and atypical intraductal proliferation (AIP) terminology, diagnostic criteria, grading, and management implications, as well as to develop uniform reporting guidelines for IDCP and AIP, endorsed by both societies. A 32-member expert panel, composed of five core members, 25 expert urological pathologists, and two expert urologists, employed a modified Delphi process consisting of multiple rounds of consultation and voting. These were supplemented by discussions at the 2025 United States and Canadian Academy of Pathologists Annual Meeting to achieve expert consensus (defined as at least 67% agreement). Consensus was reached on several key issues. IDCP was regarded most commonly as reflecting the retrograde spread of invasive prostate cancer (PCa). IDCP diagnosis should be based on the Guo and Epstein criteria, supported by basal cell immunohistochemistry in cases that are difficult to distinguish from invasive PCa. The term AIP should be used only in equivocal proliferations where IDCP is favoured but the criteria are not fully met, and these should be reported as 'AIP, suspicious for IDCP'. In the presence of invasive PCa, IDCP should generally be incorporated into Gleason grading irrespective of Grade Group (GG). However, a significant minority (30%) favoured excluding IDCP from the Gleason score if the invasive component was solely Gleason pattern (GP) 3. Pure IDCP (not associated with invasive PCa) and AIP, suspicious for IDCP, should not be graded. IDCP should not be incorporated in the grading of invasive PCa when it is spatially distinct from invasive PCa. A second opinion from a senior or dedicated GU pathologist and discussion within a multidisciplinary management setting should be considered, in the rare settings of pure IDCP or GP3 + IDCP (formerly GG1 + IDCP scenario). This joint GUPS-ISUP consultation provides unified recommendations for the diagnosis, terminology, grading, and reporting of IDCP and AIP, and will pave the way for the development of future IDCP/AIP WHO guidelines. Their adoption should reduce interobserver variation, facilitate consistent communication with clinicians, and improve patient management.

来源:Histopathology,查看原文。版权归原作者所有。

引用

  1. Shah RB, Varma M, Zhou M, et al. The Genitourinary Pathology Society and International Society of Urological Pathology Joint Expert Consultation Recommendations on intraductal carcinoma of the prostate. Histopathology. 2026. PMID: 41384645. doi:10.1111/his.70046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。